Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2026 | COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma

Kalijn Bol, MD, Radboud University Medical Center, Nijmegen, Netherlands, explores the optimal sequencing of BRAF/MEK inhibition and immunotherapy in patients with BRAF mutated melanoma. Unfavorable results from the COWBOY (NCT02968303), SECOMBIT (NCT02631447) and EBIN (NCT03235245) trials of induction BRAF/MEK inhibition prior to immunotherapy suggests that this treatment sequence will not benefit patients, however Dr Bol highlights that in patients with higher tumor load based on LDH, BRAF/MEK inhibition may have been required for a longer period than the COWBOY trial examined to provide benefit. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.